Neurocrine Biosciences, Inc.

Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia

New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings…